Format

Send to

Choose Destination
Clin Lung Cancer. 2019 Mar;20(2):e142-e147. doi: 10.1016/j.cllc.2018.11.002. Epub 2018 Nov 20.

Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.

Author information

1
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Biomarker Discovery Program, Mayo Clinic, Rochester, MN; Cancer Research Center, Shantou University Medical College, Shantou, China.
2
Department of Medical Oncology, Mayo Clinic, Rochester, MN.
3
Department of Radiology, Mayo Clinic, Rochester, MN.
4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Department of Neurology, China-Japan Friendship Hospital, Beijing, China.
5
Department of Surgery, Mayo Clinic, Rochester, MN.
6
Department of Health Science Research, Mayo Clinic, Rochester, MN.
7
Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic; Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
8
The Genome Analysis Core, Center for Individualized Medicine, Mayo Clinic, Rochester, MN.
9
Biomarker Discovery Program, Mayo Clinic, Rochester, MN.
10
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
11
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Biomarker Discovery Program, Mayo Clinic, Rochester, MN; The Genome Analysis Core, Center for Individualized Medicine, Mayo Clinic, Rochester, MN. Electronic address: jen.jin@mayo.edu.

KEYWORDS:

5′ Fusion partner; Gene fusion; SCID-Beige mice; Survival; Targeted therapy

PMID:
30581091
DOI:
10.1016/j.cllc.2018.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center